A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948)

Breast Neoplasm Clinical Trial

Official title:

Phase II Trial of Caelyx and Cyclophosphamide in Metastatic Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00779129
• Other study ID #: P02948
• Status: Completed
• Phase: Phase 2
• First received: October 23, 2008
• Last updated: September 29, 2015
• Start date: March 2003
• Est. completion date: August 2007

Study information

• Verified date: September 2015
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

Women with metastatic breast cancer are usually treated with anthracyclines (ie, doxorubicin or epirubicin) but cardiac toxicity limits their use. The aim of this study is to evaluate the safety and efficacy of Caelyx in combination with cyclophosphamide in women with metastatic breast cancer who have received adjuvant anthracyclines with or without a taxane.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: August 2007
• Est. primary completion date: August 2007
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Female, aged >=18 years.

• Subject must have histologic diagnosis of breast carcinoma.

• Subject must have documented measurable metastatic breast cancer by appropriate radiologic imaging.

• Subject must have previous anthracyclin-based adjuvant regimen and disease-free status for at least one year following the completion of adjuvant therapy.

• Subject must have ECOG performance status 0, 1, or 2.

• Subject must have life expectancy > 6 months

• Subject must have left ventricular ejection fraction >=55% as determined by MUGA scan.

• Subject must have normal organ function, except if abnormal due to tumor involvement:

• Adequate bone marrow function (platelets >=100 X 10^9/L, hemoglobin >=90 g/L, Neutrophils >=1.5 X 10^9/L)

• Adequate renal function (serum creatinine < 2 X the upper limit of normal (ULN)

• Adequate liver function (bilirubin < 2 times ULN, AST or ALT < 2 times ULN in the absence of liver metastasis, AST or ALT < 5 times ULN in the presence of liver metastasis.

• Women of childbearing potential must be using adequate contraception and have a negative pregnancy test at the time of enrollment.

• Subject must be able to understand and give informed consent.

Exclusion Criteria:

• Age > 75 years old.

• Subject who is pregnant or breastfeeding or is unwilling to use adequate contraception.

• Subject who has had a previous chemotherapy for metastatic disease.

• Subject who has history of cardiac disease, with New York Heart Association Class II or greater with congestive heart failure.

• Subject who has clinically significant hepatic disease in regard to Hepatitis B, Hepatitis C, cirrhosis, or other liver diseases unrelated to the underlying metastatic breast cancer.

• Subject who has uncontrolled bacterial, viral, or fungal infection.

• Subject who exhibits confusion or disorientation.

• Subject with any condition which would prevent adequate follow-up.

• Subject who has received radiotherapy in the last 4 weeks.

• Subject with any other active primary tumor under treatment, except basal cell carcinoma of the skin, or carcinoma in situ of the cervix.

• Subject who has brain metastasis.

• Subject who is not able to give informed consent.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Neoplasm
• Breast Neoplasms

Intervention

Drug:
• Pegylated Lyposomal Doxorubicin
Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
• Cyclophosphamide
Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.	Princess Margaret Hospital, Canada

References & Publications (1)

Trudeau ME, Clemons MJ, Provencher L, Panasci L, Yelle L, Rayson D, Latreille J, Vandenberg T, Goel R, Zibdawi L, Rahim Y, Pouliot JF. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for f — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to response; Duration of response; Time to progression; Survival		With complete or partial response, subjects will be re-evaluated 4 weeks later to confirm the initial observation; Follow-up for a minimum of one year for survival.	No
Secondary	Left ventricular ejection fraction (LVEF), (MUGA Scan); Radiological imaging; Examination of adverse events, laboratory data, vital signs		LVEF following cycles 2, 4, 5, and 6 of study drug; Radiological imaging every 6 weeks.	Yes